ARCI Controlled Therapeutic Medication Schedule for Horses - Version 4.0 Revised – April 20, 2017

Controlled Therapeutic Withdrawal Medication Threshold Dosing Specifications Reference Notes Note Guideline

10 nanograms per milliliter as 2-(1- 48 hours Single intravenous dose of Acepromazine University of California Applicable analyte is hydroxyethyl) promazine acepromazine at 0.05 at Davis project metabolite HEPS sulfoxide (HEPS) in milligrams per kilogram urine

720 micrograms total dose European Horseracing 1 nanogram per milliliter Albuterol 72 hours intra-nasal only1. Based upon Scientific Liaison See Endnote of urine dosing up to 4 times per day Committee Data

Intra-articular administration of 9 milligrams of Intra-articular dosing 10 picograms per Sodium Phosphate and only - applicable milliliter of plasma or 7 days Betamethasone RMTC study analyte is Betamethasone serum Injectable Suspension, USP betamethasone in (American Regent product plasma or serum 2 #0517-0720-01)

Applicable analytes 300 nanograms per are total butorphanol milliliter of total Journal of Veterinary Single intravenous dose of (drug and conjugates) butorphanol in urine or 2 Pharmacology and butorphanol as Torbugesic® in urine and Butorphanol nanograms of free 48 hours Therapeutics doi: (butorphanol tartrate) at 0.1 butorphanol in butorphanol per 10.1111/j.1365- milligrams per kilogram plasma (the drug milliliter per milliliter of 2885.2012.01385.x itself, not any plasma or serum conjugate)

1 Administration of albuterol by any means other than intra-nasally has a high likelihood in resulting in a positive finding. This specifically includes oral administration. Trainers and veterinarians are cautioned against using oral albuterol. 2 Intramuscular administration of will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.

ARCI Controlled Therapeutic Medications Schedule Ver. 4.0, April 2017

2

Controlled Therapeutic Withdrawal Medication Threshold Dosing Specifications Reference Notes Note Guideline

Do not administer Kentucky Equine Drug ivermectin within 48 6 nanograms per Research 0.4 milligrams per kilogram hours of a race if the Cetirizine milliliter of plasma or 48 hours Council/University of twice daily for 5 doses horse has been serum California at Davis administered study cetirizine.

Kentucky Equine Drug 400 nanograms per Research 20 milligrams per kilogram Cimetidine milliliter of plasma or 24 hours Council/University of twice daily for 7 doses serum California at Davis study

Oral administration of 140 picograms per University of California clenbuterol as Ventipulmin® milliliter of urine at Davis; Applicable analyte is Clenbuterol 14 days4 syrup (Boehringer-Ingelheim or Level of Detection in Boehringer-Ingelheim clenbuterol Vetmedica Inc., NADA 140- plasma or serum3 Vetmedica, Inc. 973) at 0.8 mcg/kg twice a day

100 picograms per Oral administration of 500 Journal of Veterinary milliliter of milligrams of dantrolene as Pharmacology and Dantrolene 5-hydroxydantrolene in paste (compounding pharmacy) Therapeutics 34, 238– plasma or serum 48 hours or capsule formulation (Proctor 246 and Gamble)

2 nanograms per milliliter of Dormosedan ™ used in study. Detomidine carboxydetomidine in KY EDRC, UC 48 hours 5 mg IV (once) urine or 1 nanogram per Davis/UF Study. milliter of detomidine in blood.

3 For Quarter Horses: Level of Detection in any permitted biological sample. 4 Clenbuterol is a prohibited substance in Quarter Horses and other breeds racing with Quarter Horses; there is no applicable withdrawal guideline for such horses.

ARCI Controlled Therapeutic Medications Schedule Ver. 4.0, April 2017

3

Controlled Therapeutic Withdrawal Medication Threshold Dosing Specifications Reference Notes Note Guideline

Intramuscular and intravenous administration of sodium Applicable analyte is 5 picograms per milliliter phosphate or oral Dexamethasone 72 hours RMTC study dexamethasone in of plasma or serum administration of plasma or serum dexamethasone at 0.05milligrams per kilogram regardless of route

Five inch ribbon topical application of 1% diclofenac 5 nanograms per Veterinary Applicable analyte is 48 hours liposomal cream formulation. Diclofenac milliliter of plasma or Therapeutics 6: 57-66 diclofenac in plasma or (Surpass Topical Anti- serum (2005) serum Inflammatory Cream, IDEXX Pharmaceuticals)

10 micrograms per Applicable analyte is Dimethyl sulfoxide 48 hours Intravenous milliliter of plasma or ARCI model rule DMSO in plasma or (DMSO) serum serum

Oral administration of firocoxib 20 nanograms per Applicable analyte is 14 days as EQUIOXX oral paste at a RMTC study Firocoxib milliliter of plasma or firocoxib in plasma or daily dose of 0.1 milligram per serum serum kilogram for four days

ARCI Controlled Therapeutic Medications Schedule Ver. 4.0, April 2017

4

Controlled Therapeutic Withdrawal Medication Threshold Dosing Specifications Reference Notes Note Guideline

100 nanogram per Must also have urine Single Intravenous dose of Furosemide milliliter of plasma or 4 hours furosemide up to 500 ARCI model rule specific gravity < serum 5 1.010 for a violation. milligram

RMTC study; Journal Single intravenous dose of 1 of Veterinary 3 picograms per milliliter milligram of glycopyrrolate as Applicable analyte is Glycopyrrolate 48 hours Pharmacology and plasma or serum Glycopyrrolate Injection, USP glycopyrrolate in Therapeutics doi: (American Regent product # plasma or serum 10.1111/j.1365- 0517-4601-25) 2885.2011.01272.x

Kentucky Equine Drug 12 nanograms per Research Guaifenesin milliliter of plasma or 48 hours 2 grams twice daily for 5 doses Council/University of serum California at Davis study

100 picograms per 10 milligrams total dose milliliter of plasma or 7 days subcutaneous or 20 milligrams RMTC Study serum total dose in one articular space

European Horseracing Applies to total major 20 picograms per 200 milligrams of lidocaine as Scientific Liaison hydroxylated Lidocaine milliliter of total 30H- its hydrochloride salt 72 hours Committee data; Iowa metabolite (i.e., lidocaine in plasma or administered subcutaneously State University study. includes conjugates) serum

5 ARCI-0110929(F)(2)(d) and ARCI-025-020(F)(2)(d) state that the dose of Furosemide “shall not exceed 500 milligrams nor be less than 150 milligrams.”

ARCI Controlled Therapeutic Medications Schedule Ver. 4.0, April 2017

5

Controlled Therapeutic Withdrawal Medication Threshold Dosing Specifications Reference Notes Note Guideline

10 nanograms total hydroxymepivacaine per Single 0.07 milligrams per European Horseracing Mepivacaine milliliter of urine or 72 hours kilogram subcutaneous dose of Scientific Liaison above Level of Detection mepivacaine Committee data of mepivacaine in plasma or serum

Single intravenous dose of 15 Journal of Veterinary 1 nanogram per milliliter milligrams per kilogram Applicable analyte is Methocarbamol 48 hours Pharmacology and of plasma or serum methocarbamol as Robaxin® or methocarbamol in Therapeutics doi: plasma or serum 5 grams orally 10.1111/jvp.12068

Total dose of Journal of Veterinary acetate Pharmacology and suspension in one articular Applicable analyte is 100 picograms per Therapeutics Methylprednisolone See Dosing space6. The recommended methylprednisolone milliliter of plasma or volume 37, Issue 2, Specifications withdrawal for serum pages 125–132, April methylprednisolone acetate is a 2014 minimum of 21 days at a 100 milligram dose

Kentucky Equine Drug omeprazole sulfide - Research GastroGuard™ used in 10 nanograms per Omeprazole 24 hours Orally (2.2 grams) once daily Council/University of the study milliliter of plasma or for 4 doses California at Davis serum study

6 Intramuscular administration of methylprednisolone acetate will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period. Please see Dosing Specifications for recommended withdrawal time.

ARCI Controlled Therapeutic Medications Schedule Ver. 4.0, April 2017

6

Controlled Therapeutic Withdrawal Medication Threshold Dosing Specifications Reference Notes Note Guideline

Applicable analyte is 1 nanogram per milliliter 48 hours prednisolone in plasma 1 milligram per kilogram orally of plasma or serum or serum

Mandatory Procaine penicillin 25 nanograms per RMTC – reference surveillance of horse (administration must be Following Intramuscular milliliter of plasma or notes online at owner’s expense 6 reported to Commission) entry to race serum hours before racing

Kentucky Equine Drug 40 nanograms per 8 milligrams per kilogram Research Ranitidine milliliter of plasma or 24 hours twice daily for 7 doses Council/University of serum California at Davis study

100 picograms per Equine Veterinary Applicable analyte is milliliter of plasma or Total dose of 9 milligram in Journal, acetonide serum 7 days 7 one articular space 10.1111/evj.12059 in plasma or serum (2013)

200 picograms per Applicable analyte is Xylazine 200 milligrams intravenously University of California milliliter of plasma or 48 hours xylazine. at Davis study serum

7 Intramuscular administration of triamcinolone acetonide will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.

ARCI Controlled Therapeutic Medications Schedule Ver. 4.0, April 2017

7

†† Non-Steroidal Anti-Inflammatory Drug (NSAID) Rules for Horses

Controlled Therapeutic Threshold Withdrawal Dosing Specifications Medication Threshold (Primary) Reference Notes (Secondary) Guideline

Secondary anti- Single intravenous dose of stacking threshold: 20 nanogram per flunixin as Banamine® (flunixin 3.0 nanograms per Flunixin University of California milliliter of plasma or 32 hours meglumine) at 1.1 milligram per milliliter of plasma or at Davis/RMTC study serum kilogram serum (Administration 48 hours prior)

Secondary anti- stacking threshold: 1 Single intravenous dose of HFL Sport Sciences/ Ketoprofen 2 nanograms per nanogram per milliliter ketoprofen as Ketofen® at 2.2 Kentucky Equine Drug milliliter of plasma or 24 hours of plasma or serum milligrams per kilogram and Research serum (Administration 48 Council/RMTC study hours prior)

Secondary anti- stacking threshold: Single intravenous dose of 2 micrograms per 0.3 micrograms per Phenylbutazone phenylbutazone at 4.0 milliliter of plasma or 24 hours ARCI model rule milliliter of plasma or milligrams per kilogram serum serum (Administration 48-hours prior)

†† Samples collected may contain one of the NSAIDs in this chart at a concentration up to the Primary Threshold. Samples may also contain another of the NSAIDs in this chart up at a concentration up to the Secondary Threshold. No more than 2 of the NSAIDs in this chart may be present in any sample.

ARCI Controlled Therapeutic Medications Schedule Ver. 4.0, April 2017

8

Recent Document Revisions

Date Version Revision Revision Description Apr-17 4.0 Clenbuterol Added footnotes establishing Clenbuterol as a prohibited substance in Quarter Horses with no applicable withdrawal guideline for Quarter Horses or breeds racing with Quarter Horses. Apr-17 4.0 Whole document Re-numbered footnotes throughout document to make them continuous

Dec-16 3.2 Omeprazole Clarified threshold for omeprazole sulfide.

Sep-16 3.1 Detomidine Amended threshold and dosing specifications. Mar-16 3 Omeprazole Amended threshold and dosing specifications Mar-16 3 Xylazine Amended threshold and dosing specifications Mar-16 3 Guaifenesin Added as New Substance to Controlled Therapeutic Medication Schedule

Mar-16 3 Cetirizine Added as New Substance to Controlled Therapeutic Medication Schedule

Mar-16 3 Ranitidine Added as New Substance to Controlled Therapeutic Medication Schedule

Mar-16 3 Cimetidine Added as New Substance to Controlled Therapeutic Medication Schedule

Apr-15 2.02 Methylprednisolone Directed readers to use Dosing Specification column for recommended withdrawal guideline. Apr-15 2.02 Furosemide Added clarifying language to Furosemide reflecting ARCI-011- 020(F)(2)(d) and ARCI-025-020(F)(2)(d) minimum and maximum thresholds

Apr-15 2.02 Added “For Horses” to Added the words “for Horses” to document title Title Apr-14 2.01 Methocarbamol Corrected dosage from 0.15 milligrams per kilogram to 15 milligrams per kilogram Apr-14 2 Dimethyl sulfoxide Removed “oral” from dosing specifications (DMSO) Apr-14 2 Xylazine Changed Note section from “Applies to xylazine and xylazine metabolite” to “Applies to analyte xylazine”

ARCI Controlled Therapeutic Medications Schedule Ver. 4.0, April 2017

9

Apr-14 2 Xylazine Corrected typographical error in Threshold from “0.01ng/mg of plasma or serum” to “0.01 nanogram per milliliter of plasma or serum”

Apr-14 2 Isoflupredone Added Isoflupredone as New Substance to Controlled Therapeutic Medication Schedule Apr-14 2 Albuterol Added Albuterol as New Substance to Controlled Therapeutic Medication Schedule Apr-14 2 Flunixin, Ketoprofen, Added Secondary Anti-Stacking Threshold Phenylbutazone Apr-14 2 Flunixin, Ketoprofen, Created separate section for Non-Steroidal Anti-Inflammatory Drugs at end of Phenylbutazone Controlled Therapeutic Medication Schedule, Relocated Flunixin, Ketoprofen, and Phenylbutazone to new section Apr-14 2 Changed Table Header from “No Pre-Race Treatment Within” to “Withdrawal Guideline” Apr-13 1 Original Controlled Therapeutic Medication Schedule Adopted by ARCI Board of Directors

ARCI Controlled Therapeutic Medications Schedule Ver. 4.0, April 2017